de Blanck Steen Riisgaard, Scherman-Rydhög Jonas, Siemsen Mette, Christensen Merete, Baeksgaard Lene, Irming Jølck Rasmus, Specht Lena, Andresen Thomas Lars, Persson Gitte Fredberg
1Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark.
2Department of Physics, Niels Bohr Institute, University of Copenhagen , Copenhagen , Denmark.
Br J Radiol. 2018 Dec;91(1092):20180236. doi: 10.1259/bjr.20180236. Epub 2018 Jul 9.
: To evaluate the feasibility of a new liquid fiducial marker for use in image-guided radiotherapy for oesophageal cancer.
: Liquid fiducial markers were implanted in patients with metastatic or inoperable locally advanced oesophageal or gastro-oesophageal junction cancer receiving radiotherapy. Markers were implanted using a conventional gastroscope equipped with a 22 G Wang needle. Marker visibility was evaluated on fluoroscopy, CT, MRI and cone beam CT scans.
: Liquid markers (n = 16) were injected in four patients. No Grade 2 or worse adverse events were observed in relation to the implantation procedure, during treatment or in the follow-up period. 12/16 (75%) markers were available at the planning CT-scan and throughout the treatment- and follow-up period. The implanted markers were adequately visible in CT and cone beam CT but were difficult to distinguish in fluoroscopy and MRI without information from the corresponding CT image.
: Liquid fiducial marker placement in the oesophagus proved safe and clinically feasible.
: This paper presents the first clinical use of a new liquid fiducial marker in patients with oesophageal cancer and demonstrates that marker implantation using standard gastroscopic equipment and subsequent use in three-dimensional image-guided radiation therapy is safe and clinically feasible.
评估一种新型液体基准标记物在食管癌图像引导放射治疗中应用的可行性。
将液体基准标记物植入接受放疗的转移性或无法手术的局部晚期食管癌或胃食管交界癌患者体内。使用配备22G王针的传统胃镜植入标记物。在荧光透视、CT、MRI和锥形束CT扫描上评估标记物的可视性。
对4例患者注射了液体标记物（n = 16）。在植入过程中、治疗期间或随访期间，未观察到2级或更严重的不良事件。12/16（75%）的标记物在计划CT扫描以及整个治疗和随访期间均可用。植入的标记物在CT和锥形束CT上清晰可见，但在荧光透视和MRI上，若无相应CT图像信息则难以区分。
在食管中放置液体基准标记物被证明是安全且临床可行的。
本文介绍了新型液体基准标记物在食管癌患者中的首次临床应用，并证明使用标准胃镜设备植入标记物并随后用于三维图像引导放射治疗是安全且临床可行的。
